Sell Gold for Bitcoin? (and This?)

From Legacy Research | Ad

It’s a controversial call.

But former Wall Street VP and hedge fund manager Teeka Tiwari says he “no longer expects gold to adequately protect your wealth against the money printing happening right now.”

And for the first time in Palm Beach Research Group history, an editor is telling readers to sell gold… and buy Bitcoin.

But this is about more than just one coin…

ANVS Insider Trading (Annovis Bio)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 42.60%

Insider Buying (Last 12 Months): $520,791.46

Insider Selling (Last 12 Months): $0.00

Annovis Bio Insider Trading History Chart

Annovis Bio Share Price & Price History

^$28.89

▼ -0.5 (-1.70%)

As of 10/22/2021 05:00 PM ET

Days: 30 | 90 | 365

Former Tech Executive Issues Urgent Plea

From Legacy Research | Ad

"I'm not trying to scare you...

But for many people - life is about to take a very strange turn."

Click to Hear His New Warning.

Annovis Bio Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/11/2021	Claudine Bruck	Director	Buy	181	$27.66	$5,006.46
10/11/2021	Maria-Luisa Maccecchini	CEO	Buy	18,000	$27.61	$496,980.00
8/19/2021	Reid Mccarthy	Director	Buy	500	$37.61	$18,805.00	6,829

Insider Trading at Annovis Bio?

Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Annovis Bio and related companies.

SEC Filings (Institutional Ownership Changes) for Annovis Bio (NYSE:ANVS)

15.60% of Annovis Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Annovis Bio Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
10/21/2021	Essex LLC	11,962	$0.38M	0.1%	N/A	0.148%
9/17/2021	Virtu Financial LLC	17,442	$1.49M	0.1%	+119.4%	0.215%
9/3/2021	Parametric Portfolio Associates LLC	22,331	$1.91M	0.0%	N/A	0.276%
8/23/2021	Morgan Stanley	30,070	$2.57M	0.0%	N/A	0.371%
8/18/2021	Ikarian Capital LLC	103,527	$8.86M	0.7%	-46.5%	1.278%
8/17/2021	Wells Fargo & Company MN	537	$47K	0.0%	+2,048.0%	0.007%
8/17/2021	Worth Venture Partners LLC	33,834	$2.90M	1.1%	+12.9%	0.418%
8/17/2021	Knoll Capital Management LLC	39,210	$3.36M	1.8%	N/A	0.484%
8/17/2021	Millennium Management LLC	3,587	$0.31M	0.0%	N/A	0.044%
8/17/2021	Price T Rowe Associates Inc. MD	3,000	$0.26M	0.0%	N/A	0.037%
8/17/2021	Boothbay Fund Management LLC	11,756	$1.01M	0.0%	-46.5%	0.145%
8/17/2021	Bridgeway Capital Management LLC	23,600	$2.02M	0.0%	+4.9%	0.291%
8/16/2021	Cubist Systematic Strategies LLC	4,508	$0.39M	0.0%	N/A	0.056%
8/16/2021	Morgan Stanley	30,070	$2.57M	0.0%	N/A	0.371%
8/16/2021	Diametric Capital LP	12,458	$1.07M	0.8%	-26.0%	0.154%
8/16/2021	State Street Corp	17,300	$1.48M	0.0%	N/A	0.214%
8/16/2021	Goldman Sachs Group Inc.	25,819	$2.21M	0.0%	N/A	0.319%
8/13/2021	Northern Trust Corp	9,098	$0.78M	0.0%	+22.5%	0.112%
8/13/2021	RKL Wealth Management LLC	5,000	$0.43M	0.1%	-50.0%	0.062%
8/13/2021	Wealthspire Advisors LLC	5,000	$0.43M	0.0%	-50.0%	0.062%
8/13/2021	LPL Financial LLC	3,868	$0.33M	0.0%	N/A	0.048%
8/13/2021	Geode Capital Management LLC	38,569	$3.30M	0.0%	+39.8%	0.476%
8/13/2021	Vanguard Group Inc.	229,453	$19.64M	0.0%	+56.1%	2.832%
8/13/2021	EAM Global Investors LLC	29,590	$2.53M	0.7%	N/A	0.365%
8/13/2021	EAM Investors LLC	48,643	$4.16M	0.6%	+9.0%	0.600%
8/12/2021	AIGH Capital Management LLC	126,469	$10.82M	1.9%	+7.9%	1.561%
8/12/2021	JPMorgan Chase & Co.	8,024	$0.69M	0.0%	N/A	0.099%
8/12/2021	L & S Advisors Inc	19,530	$1.67M	0.2%	N/A	0.241%
8/11/2021	Commonwealth Equity Services LLC	3,964	$0.34M	0.0%	N/A	0.049%
8/11/2021	Bank of New York Mellon Corp	22,168	$1.90M	0.0%	N/A	0.274%
8/11/2021	BlackRock Inc.	100,997	$8.64M	0.0%	N/A	1.247%
8/11/2021	Deutsche Bank AG	4,367	$0.37M	0.0%	N/A	0.054%
8/11/2021	Redmond Asset Management LLC	7,750	$0.66M	0.2%	N/A	0.096%
8/10/2021	Virtus ETF Advisers LLC	2,518	$0.22M	0.1%	N/A	0.031%
8/10/2021	National Asset Management Inc.	2,430	$0.21M	0.0%	N/A	0.030%
8/9/2021	Broderick Brian C	4,000	$0.34M	0.1%	N/A	0.049%
8/9/2021	Cannell Peter B & Co. Inc.	16,000	$1.37M	0.0%	+60.0%	0.198%
8/6/2021	Sei Investments Co.	15,244	$1.31M	0.0%	N/A	0.188%
8/5/2021	US Bancorp DE	500	$43K	0.0%	N/A	0.006%
8/3/2021	Absher Wealth Management LLC	6,329	$0.54M	0.1%	N/A	0.078%
8/2/2021	Advisor Group Holdings Inc.	1,742	$0.15M	0.0%	-58.5%	0.022%
8/2/2021	Modera Wealth Management LLC	34,746	$2.97M	0.2%	-14.5%	0.429%
7/31/2021	Sterling Investment Advisors Ltd.	20,574	$1.76M	0.5%	-35.1%	0.254%
6/10/2021	Lokken Investment Group LLC	17,411	$0.49M	0.4%	-45.9%	0.251%
5/19/2021	Virtu Financial LLC	7,951	$0.22M	0.0%	N/A	0.114%
5/19/2021	Worth Venture Partners LLC	29,968	$0.84M	0.4%	-74.9%	0.431%
5/19/2021	Diametric Capital LP	16,837	$0.47M	0.4%	N/A	0.242%
5/18/2021	Citadel Advisors LLC	8,963	$0.25M	0.0%	N/A	0.129%
5/17/2021	Ikarian Capital LLC	193,368	$5.40M	0.2%	N/A	2.783%
5/14/2021	Brown Advisory Inc.	7,442	$0.21M	0.0%	-50.2%	0.107%
5/13/2021	Renaissance Technologies LLC	19,900	$0.56M	0.0%	N/A	0.286%
5/12/2021	Northern Trust Corp	7,425	$0.21M	0.0%	N/A	0.107%
5/12/2021	Geode Capital Management LLC	27,583	$0.77M	0.0%	N/A	0.397%
5/11/2021	EAM Investors LLC	44,640	$1.25M	0.2%	N/A	0.643%
5/10/2021	RKL Wealth Management LLC	10,000	$0.28M	0.0%	N/A	0.144%
5/4/2021	Sterling Investment Advisors Ltd.	31,678	$0.88M	0.3%	-37.4%	0.456%
4/23/2021	BRYN MAWR TRUST Co	14,643	$0.41M	0.0%	N/A	0.211%
2/11/2021	Modera Wealth Management LLC	43,846	$0.33M	0.0%	N/A	0.635%
2/8/2021	Lokken Investment Group LLC	32,211	$0.24M	0.2%	N/A	0.466%

Data available starting January 2016

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Today's Range

Now: $28.89

$28.02

$29.24

50 Day Range

MA: $33.95

$25.67

$41.82

52 Week Range

Now: $28.89

$4.14

$132.00

Volume

67,163 shs

Average Volume

715,122 shs

Market Capitalization

$234.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.17

Who are the company insiders with the largest holdings of Annovis Bio?: Annovis Bio's top insider investors include:
Reid Mccarthy (Director)
Claudine Bruck (Director)
Maria-Luisa Maccecchini (CEO)
Who are the major institutional investors of Annovis Bio?: Annovis Bio's top institutional shareholders include:
Essex LLC — 0.15%
Which institutional investors are buying Annovis Bio stock?: Within the last quarter, ANVS stock was bought by institutional investors including:
Essex LLC
During the last year, these company insiders have bought Annovis Bio stock:
Reid Mccarthy (Director)
Claudine Bruck (Director)
Maria-Luisa Maccecchini (CEO)

Charles Payne reveals his market-beating strategy

From Invest Like Charles | Ad

You can learn how the best on Fox Business makes his decisions… see his portfolio and how he analyzes new opportunities.

Reserve Your Free eTicket Now